UTY (KDM6C) in Cancer: Epigenetic Regulation, Tumour Suppressor Functions, and Clinical Implications
Epigenomes · 09.05.2026 · 10 (2) · 31
DOI: 10.3390/epigenomes10020031 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Epigenomes, online erschienen am 09.05.2026. Verfasst von Chitrakshi Chopra und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, All India Institute of Medical Sciences, Vijaypur, Jammu 181134, India. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Indian Council of Medical Research, ICMR New Delhi.
Abstract (Originalsprache)
The ubiquitously transcribed tetratricopeptide repeat Y-linked gene (UTY/KDM6C), a catalytically impaired histone demethylase encoded on the Y chromosome, has garnered increasing attention for its emerging roles in tumorigenesis and cancer progression. Despite high sequence homology with its X-linked paralog UTX/KDM6A, UTY exhibits markedly reduced or absent H3K27me3 demethylase activity due to critical amino acid substitutions in its Jumonji C domain. Consequently, UTY primarily functions through non-enzymatic mechanisms, acting as a scaffold in chromatin-remodelling complexes like COMPASS and SWI/SNF, or mediating protein–protein interactions that regulate transcriptional programs independent of demethylation. This aligns with epigenetic dysregulation in cancers, where imbalances in repressive H3K27me3 and active H3K4me either drive tumour suppressor silencing or oncogene activation. Unlike frequently mutated UTX in cancers such as breast, renal cell carcinoma, and acute myeloid leukaemia, UTY’s contributions in cancer are less defined, constrained by male-specific expression. Emerging evidence suggests UTY as a context-dependent tumour suppressor in AML and squamous-like pancreatic ductal adenocarcinoma. While direct functional validation remains limited in several cancer types, UTY is increasingly implicated as a potential tumour suppressor in haematological malignancies and prostate cancer. Therapeutically targeting UTY’s scaffold functions shows promise for male-specific cancers and merits future investigation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biochemistry, All India Institute of Medical Sciences, Vijaypur, Jammu 181134, India.
- Department of Medical Oncology (Laboratory), Dr. Bhim Rao Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India.
ORCID-Profile: Chandra Prakash Prasad, Manish Kumar
Förderung
- Indian Council of Medical Research
- ICMR New Delhi
Zitieren
APA
Chopra, C., Prasad, C. P., & Kumar, M. (2026). UTY (KDM6C) in Cancer: Epigenetic Regulation, Tumour Suppressor Functions, and Clinical Implications. Epigenomes, 10(2), 31. https://doi.org/10.3390/epigenomes10020031
Vancouver
Chopra C, Prasad CP, Kumar M. UTY (KDM6C) in Cancer: Epigenetic Regulation, Tumour Suppressor Functions, and Clinical Implications. Epigenomes. 2026;10(2):31. doi:10.3390/epigenomes10020031
BibTeX
@article{Chopra2026,
author = {Chopra, Chitrakshi and Prasad, Chandra Prakash and Kumar, Manish},
title = {UTY (KDM6C) in Cancer: Epigenetic Regulation, Tumour Suppressor Functions, and Clinical Implications},
journal = {Epigenomes},
year = {2026},
volume = {10},
number = {2},
pages = {31},
doi = {10.3390/epigenomes10020031}
}
EUVIMED